Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: J Hepatol. 2021 Feb 18;75(1):163–176. doi: 10.1016/j.jhep.2021.02.004

Figure 1. Il20−/− mice are resistant to ConA-mediated acute hepatitis by elevating hepatoprotective cytokine IL-6 in the liver.

Figure 1.

(A) C57BL/6N mice (n=6) were intravenously injected with ConA (12 mg/kg). Serum IL-20 levels were measured. (B-H) WT (n=8) and Il20−/− mice (n=10) were intravenously injected with ConA. (B) RT-qPCR of IL-20 mRNA levels. (C) Serum ALT and AST levels. (D) Representative images of H&E staining are shown, the percentage of necrotic area per field was quantified. (E, F) Serum cytokine levels and hepatic cytokine mRNA levels. (G, H) Western blot analyses of IL-6 and IFN-γ downstream signaling pathways, and pro- and anti-apoptotic protein levels in the liver post ConA injection. Values represent means ± SD. *P< 0.05, **P< 0.01, ***P< 0.001. ConA: Concanavalin A.